| Symbol | MBX |
|---|---|
| Name | MBX BIOSCIENCES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 12406 HORESHAM,STREET, CARMEL, Indiana, 46032, United States |
| Telephone | 3179893100 |
| Fax | — |
| — | |
| Website | https://www.mbxbio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001776111 |
| Description | MBX Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. We are advancing a pipeline of novel candidates for endocrine and metabolic disorders. Our lead product candidate, MBX 2109, is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism, or HP. We designed MBX 2109 to treat the underlying pathophysiology of HP by providing a continuous, infusion-like exposure to parathyroid hormone, or PTH, with convenient once-weekly administration. Additional info from NASDAQ: |
📋 Bartram Richard (Ex-Officer) plans to sell 15K shares of MBX Biosciences, Inc. (at $36.95 each, total $554K) Filed: May 13, 2026 | ID: 003576
Read moreAzoulay Salomon 🟡 adjusted position in 70.0K shares (2 derivative) of MBX Biosciences, Inc. (MBX) at $38.38 ($4.3M) Transaction Date: May 08, 2026 | Filing ID: 216704
Read more📋 Bartram Richard (Ex-Officer) plans to sell 22K shares of MBX Biosciences, Inc. (at $44.08 each, total $992K) Filed: May 11, 2026 | ID: 003490
Read moreMBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
Read more📋 Azoulay Salomon (Officer) plans to sell 70K shares of MBX Biosciences, Inc. (at $38.37 each, total $2.7M) Filed: May 08, 2026 | ID: 003434
Read moreAzoulay Salomon 🔴 sold 231 shares of MBX Biosciences, Inc. (MBX) at $29.54 Transaction Date: May 06, 2026 | Filing ID: 214582
Read moreHawryluk P. Kent 🔴 sold 607 shares of MBX Biosciences, Inc. (MBX) at $29.54 Transaction Date: May 06, 2026 | Filing ID: 214574
Read moreNew Form DEFA14A - MBX Biosciences, Inc. <b>Filed:</b> 2026-05-08 <b>AccNo:</b> 0001193125-26-214615 <b>Size:</b> 88 KB
Read more📋 Bartram Richard (Ex-Officer) plans to sell 10K shares of MBX Biosciences, Inc. (at $37.96 each, total $380K) Filed: May 08, 2026 | ID: 003419
Read more📋 Bartram Richard (Ex-Officer) plans to sell 10K shares of MBX Biosciences, Inc. (at $32.20 each, total $322K) Filed: May 07, 2026 | ID: 003370
Read more